Judith Salerno, MD, MS, named as next President of The New York Academy of Medicine

Published on:

NEW YORK, June 14, 2017 /PRNewswire-USNewswire/ -- The Board of Trustees of The New York Academy of Medicine is pleased to announce Judith Salerno, MD, MS, as its next President, effective September 5, 2017.

Dr. Salerno is a physician executive who most recently was President and Chief Executive Officer of the Susan G. Komen Breast Cancer Foundation. Her prior leadership experience includes serving as the Leonard D. Schaeffer Executive Officer of the Institute of Medicine (now National Academy of Medicine) of the US National Academies, the Deputy Director of the National Institute on Aging at the National Institutes of Health, Chief Consultant for Geriatrics and Extended Care for the US Veterans Health Administration, and Chief of Geriatrics at the Washington DC VA Medical Center. A board-certified physician in internal medicine, Dr. Salerno earned her medical degree from Harvard Medical School and a Master of Science degree in Health Policy and Management from the Harvard School of Public Health.

"As one of our nation's pre-eminent leaders in health and health care, we are truly excited that she will be leading the Academy as our next President," said George E. Thibault, MD, chairman of the Academy. "She has the perfect blend of clinical, research, and health policy experience that spans both government and nonprofit sectors."

"It is an honor for me to join The New York Academy of Medicine," said Dr. Salerno. "Throughout its history, the Academy has always addressed the most critical health challenges facing cities, and I look forward to continuing to advance its mission to promote the health and well-being of people in New York and cities worldwide."

As announced last fall, Dr. Jo Ivey Boufford, the current President of the Academy, will complete her 10-year tenure this summer. "We are deeply indebted to Jo's leadership over the past ten years," said Dr. Thibault. "She has elevated the stature and importance of this great institution, and its role in advancing the health and well-being of people in cities, particularly in the areas of population health, health disparities and healthy aging."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.